DI BENEDETTO, PAOLA
 Distribuzione geografica
Continente #
NA - Nord America 4.140
AS - Asia 2.249
EU - Europa 2.100
SA - Sud America 209
Continente sconosciuto - Info sul continente non disponibili 186
AF - Africa 37
OC - Oceania 6
Totale 8.927
Nazione #
US - Stati Uniti d'America 4.067
SG - Singapore 973
IE - Irlanda 535
CN - Cina 499
RU - Federazione Russa 440
SE - Svezia 224
IT - Italia 216
HK - Hong Kong 212
VN - Vietnam 209
TR - Turchia 198
BR - Brasile 182
DE - Germania 174
UA - Ucraina 131
GB - Regno Unito 119
FR - Francia 82
FI - Finlandia 61
IN - India 49
CA - Canada 47
NL - Olanda 31
BE - Belgio 28
JP - Giappone 21
BD - Bangladesh 17
MX - Messico 13
ID - Indonesia 11
PL - Polonia 11
ZA - Sudafrica 11
ES - Italia 10
IQ - Iraq 9
AR - Argentina 8
CZ - Repubblica Ceca 8
EC - Ecuador 8
KR - Corea 6
DZ - Algeria 5
LT - Lituania 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AT - Austria 4
AU - Australia 4
JM - Giamaica 4
LB - Libano 4
PK - Pakistan 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
CH - Svizzera 3
CO - Colombia 3
EG - Egitto 3
EU - Europa 3
IL - Israele 3
JO - Giordania 3
KW - Kuwait 3
MA - Marocco 3
MK - Macedonia 3
MY - Malesia 3
PH - Filippine 3
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GR - Grecia 2
HR - Croazia 2
KZ - Kazakistan 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
SN - Senegal 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KE - Kenya 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
SC - Seychelles 1
TH - Thailandia 1
UY - Uruguay 1
Totale 8.746
Città #
Chandler 603
Dublin 535
Jacksonville 530
Singapore 523
San Jose 405
Ashburn 277
Dallas 218
Hong Kong 208
Santa Clara 184
Boardman 148
Izmir 137
Council Bluffs 130
New York 119
The Dalles 103
Beijing 100
Ann Arbor 95
L'aquila 82
Nanjing 80
Lawrence 75
Moscow 75
Princeton 75
Ho Chi Minh City 67
Los Angeles 66
Wilmington 64
San Mateo 44
Dearborn 42
Hanoi 41
Woodbridge 35
Nanchang 31
Amsterdam 29
Milan 29
Dong Ket 26
L’Aquila 26
Columbus 25
Lauterbourg 25
Brussels 24
Munich 24
Helsinki 22
São Paulo 22
Hefei 21
Shanghai 21
Tokyo 21
Verona 19
Seattle 17
Kunming 16
Mountain View 16
Orem 16
Shenyang 16
Jiaxing 14
Montreal 14
Chennai 13
Houston 13
Des Moines 12
Haiphong 12
Frankfurt am Main 11
Hebei 11
San Francisco 11
Tianjin 11
Zhengzhou 11
Chicago 10
Johannesburg 10
Pune 10
Warsaw 10
Changsha 9
Guangzhou 9
Ningbo 9
Stockholm 9
Atlanta 8
Grafing 8
Jinan 8
Norwalk 8
Rome 8
Jakarta 7
Mumbai 7
Phoenix 7
Poplar 7
Queens 7
Brno 6
London 6
Manchester 6
Naples 6
Rio de Janeiro 6
Toronto 6
Bremen 5
Denver 5
Edinburgh 5
Hangzhou 5
Lanzhou 5
Nuremberg 5
Pescara 5
Ankara 4
Brasília 4
Brooklyn 4
Da Nang 4
Erbil 4
Falkenstein 4
Fremont 4
Leuven 4
Madrid 4
Mexico City 4
Totale 5.902
Nome #
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 183
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 158
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 158
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 156
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 155
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 155
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 154
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 153
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 151
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 149
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 144
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 143
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 142
Cardiovascular disease in primary sjögren’s syndrome 141
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 138
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 137
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 137
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 137
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 134
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 132
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 131
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 131
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 128
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 127
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 127
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 125
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 125
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 125
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 124
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 124
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 122
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 121
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 120
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 119
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 119
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 117
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 116
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 116
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 115
Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases 115
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 113
Interstitial lung disease in systemic sclerosis: current and future treatment. 113
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 112
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 111
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al 111
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 111
Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study 110
Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: A pilot study 109
Cellular players in angiogenesis during the course of systemic sclerosis. 108
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 108
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 108
The Vessels Contribute to Fibrosis in Systemic Sclerosis 107
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 107
Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis 107
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 107
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 104
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 103
Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort 102
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 101
FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis 100
Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC) 98
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 94
Association between clinical, histopathological and molecular features in primary Sjogren's Syndrome: a retrospective study 94
Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives 93
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome 92
Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC). 91
THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers 90
Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF 90
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2 88
Mesenchymal stem cells transplantation in Systemic Sclerosis: comment on the article by ATJ Maria et al 87
VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION. 82
 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 81
Potential of stem cells in the treatment of rheumatic disease 80
Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor 72
Phenotypical and functional characteristics of in vitro-expanded adipose-derived mesenchymal stromal cells from patients with systematic sclerosis 70
SAT0641 Performance and agreement of different operators and histological techniques for the assessment of germinal centres in minor salivary glands in primary sjÖgren’s syndrome 69
Totale 8.927
Categoria #
all - tutte 39.232
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.232


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022432 0 16 97 38 11 10 4 24 33 38 37 124
2022/20231.580 113 115 29 199 108 166 2 95 675 12 46 20
2023/2024377 60 21 21 29 35 132 9 16 1 15 4 34
2024/20251.492 38 28 146 56 230 121 165 92 330 69 119 98
2025/20262.809 198 260 143 313 282 208 472 92 255 360 186 40
2026/2027112 69 43 0 0 0 0 0 0 0 0 0 0
Totale 8.927